The UT Southwestern Physician Scientist Oncology Training Program will provide fellows and residents who have finished their clinical training in oncology the opportunity and protected time to develop the technical and Intellectual skills for a successful laboratory based oncology research program. The program will accomplish this by providing highly Individualized mentorship, the opportunity to train in the research laboratories of one of our internationally renowned faculty and up to three years of stipend support during the years of their research training. Specifically, the goals of the program are to support physicians who have finished their subspecialty clinical training in oncology and train them in lab-based translational oncology research, by providing (a) training in the laboratory skills necessary to investigate the pathogenesis and biology of cancer, (b) a rigorous mentoring and didactic program in the biology of cancer, biostatistics, ethics, and regulatory issues, (c) and training in the investigation of basic cancer questions which are clinically relevant, and in the translation of clinical observations into hypothesis based laboratory questions. Trainees will be mentored primarily by scientists who participate in one of the five programs in the Cancer Center, but will also have secondary, clinical research resource faculty mentors to ensure that the trainee develops the clinical skills and expertise necessary to succeed in a multi-disciplinary approach to the study of clinically relevant cancer questions. Unique opportunities of the program include the outstanding faculty of Cancer Biology Training Program for pre-and post doctoral PhDs within the Graduate School of Biological Sciences, a Specialized Program of Research Excellence in Lung Cancer, and a Program Project Grant on the Concerted Chemical, Biophysical and Molecular Biological Attack of Intracellular Pathways Relevant to Human Cancer. 20 laboratory mentors representing 15 different Departments and Centers are committed to this program, as are 11 clinical resource mentors. A Steering Committee consisting of 7 senior physician and scientist leaders in the Cancer Center will provide oversight and direction, and administrative support will be provided by the Cancer Center.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Sw Medical Center Dallas
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Dietrich, Martin Frederik; Yan, Shirley Xiao; Schiller, Joan Hoff (2015) Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met-Amplified Adenocarcinoma of the Lung. J Thorac Oncol 10:e23-5
Kirane, Amanda; Ludwig, Kathleen F; Sorrelle, Noah et al. (2015) Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. Cancer Res 75:3699-705
Dietrich, Martin F; Cavuoti, Dominick; Landay, Michael et al. (2014) Histological Regression of Giant Cell Tumor of Bone Following RANK Ligand Inhibition. J Investig Med High Impact Case Rep 2:2324709614560216
Singel, Stina M; Batten, Kimberly; Cornelius, Crystal et al. (2014) Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways. Breast Cancer Res 16:R28
Singel, Stina Mui; Cornelius, Crystal; Batten, Kimberly et al. (2013) A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer. Clin Cancer Res 19:2061-70
Chen, Kenneth S; Amatruda, James F (2013) A big catch for germ cell tumour research. PLoS Genet 9:e1003481
Cantrell, Leigh A; Havrilesky, Laura; Moore, Dominic T et al. (2012) A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol 127:22-6
Kirane, Amanda; Toombs, Jason E; Ostapoff, Katherine et al. (2012) Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin Cancer Res 18:5031-42
Kirane, Amanda; Toombs, Jason E; Larsen, Jill E et al. (2012) Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. Carcinogenesis 33:1639-46